Xeljanz Lawsuit: How the Pfizer Case Ended (2026)

What the Xeljanz Lawsuit Was About

The lawsuit centered on whether Pfizer properly warned about a serious infection risk. Xeljanz (tofacitinib) belongs to a drug class called Janus kinase, or JAK, inhibitors, which calm an overactive immune system. The FDA approved Xeljanz on November 6, 2012, for adults with moderate to severe rheumatoid arthritis. The agency later cleared it for psoriatic arthritis and ulcerative colitis as well.

Marilyn Stube of Arkansas started taking Xeljanz in March 2013, according to the court's March 2020 order. In March 2017, she went to a Hot Springs hospital with shoulder pain and returned days later with fever, vomiting, and trouble breathing. She then went into septic shock from a Group A strep infection. The infection led to multi-organ failure and gangrene, and surgeons had to remove both of her arms and both of her legs.

Mrs. Stube and her husband, Thomas, filed suit in July 2019. Their main argument was that Pfizer did not warn U.S. patients about sepsis, even though labels in Europe carried that warning. The complaint listed six state law claims, including failure to warn, negligence, gross negligence, and fraud, and asked for punitive damages. Punitive damages are extra money meant to punish a company, not just to repay losses.

FDA and Research Warnings Behind the Claims

Much of what people now know about Xeljanz risks came from one study. When the FDA approved the drug, it required a large safety trial comparing Xeljanz with older drugs called TNF blockers. In February 2019, the agency warned that the trial had found more deaths and more lung clots among patients on a higher dose.

In July 2019, the FDA added a Boxed Warning about blood clots and death tied to the 10 mg twice-daily dose. It also told doctors to save Xeljanz for ulcerative colitis patients who had not done well on TNF blockers. A Boxed Warning is the FDA's most serious label warning.

The picture grew worse in 2021. In February, the FDA reported that early trial data showed more serious heart problems and cancer with Xeljanz than with TNF blockers. By September, the agency required Boxed Warning updates for Xeljanz and two similar drugs, covering heart events, cancer, blood clots, and death. The FDA also advised reserving these drugs for patients who had not responded to or could not tolerate TNF blockers.

The full trial results were published in January 2022. Among more than 4,300 rheumatoid arthritis patients aged 50 or older with at least one heart risk factor, 3.4% of Xeljanz users had a major heart event, versus 2.5% on a TNF blocker. Cancer rates were 4.2% and 2.9%. Researchers concluded that Xeljanz failed to show it was as safe as the comparison drugs on both counts.

European regulators followed. The European Medicines Agency proposed new limits on JAK inhibitors, including Xeljanz, in late October 2022. It advised using them in people 65 or older, smokers, and those at higher risk of heart disease or cancer only when no suitable alternative exists.

How the Court Handled Pfizer's Bid to Dismiss

Pfizer tried to end the case early. The company filed a motion to dismiss in September 2019, arguing the claims were not properly pleaded. Chief Judge Susan O. Hickey split the difference in a March 13, 2020, order.

The judge dismissed the fraud and negligent misrepresentation claims. She also dismissed claims based on the idea that Pfizer had to warn Mrs. Stube or the public directly, rather than her doctors. Both rulings were without prejudice, which means the claims could, in theory, be refiled. Every other claim stayed in the case, including the central failure-to-warn claim.

Settlements and How the Case Ended

The Stube case closed quietly. On July 14, 2020, Pfizer filed a stipulation of dismissal with prejudice, and Judge Hickey signed an order ending the case the same day. A stipulation is a joint agreement between both sides. Dismissal with prejudice means the claims can never be brought again.

The court docket records the order as a settlement order, but no terms were ever made public. There was no trial, no jury verdict, and no public payout figure. The case also stood alone in federal court. It was never part of a multidistrict litigation (MDL), where many similar cases are grouped before one judge, and it was never a class action.

For readers, the key takeaway is simple. There is no public Xeljanz settlement fund, no court-approved payout schedule, and no ongoing group case that new claimants could join.

Filing Deadlines for Xeljanz Claims

Every state sets a time limit, called a statute of limitations, for injury claims. In Arkansas, where the Stube case was filed, product liability suits generally must start within three years of the injury. The Stubes filed in July 2019, a little over two years after the 2017 infection that led to Mrs. Stube's amputations.

Deadlines vary a great deal from state to state, and some rules can pause or shorten the clock. Because the major FDA warnings date back to 2019 and 2021, many possible claims tied to them may now be time-barred. Anyone with questions about their own situation may want to speak with a licensed attorney in their state.